Drug discovery and development – Page 2
-
ResearchRevived claims that antibiotics don’t kill bacteria with reactive oxygen prove controversial
Researchers say that multiple lines of evidence for hypothesis have now been undermined
-
NewsCould Crispr cure HIV?
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at evading eradication
-
OpinionA robotic helping hand
Mechanical labmates are making huge progress, but there are still big challenges to overcome
-
ResearchAI-designed antibodies target antigens with atomic precision
Epitope-binding proteins designed from scratch by generative AI model
-
ResearchAI cut development time of antibiotic that spares gut-friendly bacteria by two years
Animal tests show promise to target invasive strain of E. coli but approval for use in humans is still years away
-
BusinessPfizer and Novo Nordisk’s battle over Metsera
Lawsuits fly in bidding war over developer of next generation weight loss drugs
-
ResearchNanobodies from alpacas and llamas could hold the key to a universal antivenom
Novel nanobody mix protects against 17 African snake species
-
BusinessNovartis spends on deals to offset patent losses
$12 billion Avidity acquisition is the latest pipeline-pumping transaction
-
ResearchThis fragment-based drug discovery library is designed to be sociable
Study targets a key bottleneck in hit to lead optimisation by designing fragments that are both structurally diverse and easy to elaborate
-
WebinarSYNTHIA for chemists: faster route design
Discover how SYNTHIA accelerates retrosynthesis by helping chemists design, compare and refine routes with customisable filters and commercial building blocks
-
ResearchUltrapotent thrombin inhibitor combines peptide fragments from a trio of blood-sucking organisms
Hybrid molecule featuring leech, tsetse fly and flea peptide fragments binds thrombin at three sites
-
WebinarDeveloping a CITK protein degrader using the QuicTPD™ platform
Learn about the latest technology to accelerate the design of cancer treatments
-
BusinessArvinas and Pfizer seek a new home for protein degrader drug
Companies offer bifunctional cancer drug vepdegestrant to new partners after disappointing trial results
-
BusinessNovo Nordisk’s new chief cuts 9000 jobs
Danish firm shifts strategy after struggling to capitalise on its weight loss drugs
-
OpinionIs UK pharma really ‘uninvestable’?
Merck & Co, AstraZeneca (AZ) and Eli Lilly pulling UK projects highlights the precarious position of the country’s life sciences industry
-
BusinessUK loses life sciences investment as pharma companies halt expansion plans
Industry seeks greater share of healthcare spending to support innovation
-
WebinarIon suppression correction and normalisation in metabolomics
Join us to learn new ways to improve data consistency with mass spectrometry
-
OpinionLiver toxicity remains an unpredictable hurdle for medicinal chemists
The liver’s complex role in metabolising drugs makes it both a critical consideration and potential stumbling block
-
WebinarLipidomics for antibiotic resistance (AMR) mechanisms
Discover how microbial antibiotic exposure triggers lipidomic changes, offering insight into how lipids contribute to resistance mechanisms
-
ResearchNew class of antifungals show potent effects against priority pathogens
Coniotins, found in another fungus, is effective against drug-resistant pathogenic fungi